NCT05865535 - A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

June 30, 2026

Conditions

Cachexia

Interventions

BIOLOGICAL

AV-380

AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Trial Locations (12)

11967

RECRUITING

New York Cancer And Blood Specialists, Shirley

29425

RECRUITING

MUSC Hollings Cancer Center, Charleston

32804

RECRUITING

Advent Health Orlando Hospital, Orlando

37232

RECRUITING

Vanderbilt University Henry-Joyce Cancer Clinic, Nashville

68130

RECRUITING

Nebraska Cancer Specialists, Omaha

77339

RECRUITING

Community Clinical Trials, Kingwood

90211

RECRUITING

Beverly Hills Cancer Center, Beverly Hills

90712

RECRUITING

Cancer and Blood Specialty Clinic, Lakewood

92663

RECRUITING

Hoag Memorial Hospital, Newport Beach

97239

RECRUITING

Oregon Health and Science University, Portland

06102

RECRUITING

Hartford Hospital, Hartford

08816

RECRUITING

Astera Cancer Care, East Brunswick